Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.

× No keyword cloud information.

7 in total

1. Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma.

Authors: Umit Tapan; Sarah K May; Joseph Fiore; Olga Kozyreva
Journal: Leuk Lymphoma Date: 2011-02-10

2. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.

Authors: J Judy Chang; Fiona Wightman; Angeline Bartholomeusz; Anna Ayres; Stephen J Kent; Joseph Sasadeusz; Sharon R Lewin
Journal: J Virol Date: 2005-03 Impact factor: 5.103

Review 3. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.

Authors: María Luisa Manzano-Alonso; Gregorio Castellano-Tortajada
Journal: World J Gastroenterol Date: 2011-03-28 Impact factor: 5.742

Review 4. Prevention of hepatitis B virus reactivation under rituximab therapy.

Authors: Yutaka Tsutsumi; Yoshiya Yamamoto; Junji Tanaka; Masahiro Asaka; Masahiro Imamura; Nobuo Masauzi
Journal: Immunotherapy Date: 2009-11 Impact factor: 4.196

5. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer.

Authors: A Klippstein; C P Schneider; H G Sayer; K Höffken
Journal: J Cancer Res Clin Oncol Date: 2003-05-17 Impact factor: 4.553

6. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.

Authors: Marco Picardi; Fabrizio Pane; Concetta Quintarelli; Amalia De Renzo; Annalisa Del Giudice; Bianca De Divitiis; Marcello Persico; Rosanna Ciancia; Francesco Salvatore; Bruno Rotoli
Journal: Haematologica Date: 2003-11 Impact factor: 9.941

7. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

Authors: Mónica Vigna-Perez; Berenice Hernández-Castro; Octavio Paredes-Saharopulos; Diana Portales-Pérez; Lourdes Baranda; Carlos Abud-Mendoza; Roberto González-Amaro
Journal: Arthritis Res Ther Date: 2006-05-05 Impact factor: 5.156

7 in total

5 in total

Review 1. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.

Authors: Wolfram Brugger; Michele Ghielmini
Journal: Oncologist Date: 2013-07-30

Review 2. Hepatitis B virus reactivation with a rituximab-containing regimen.

Authors: Yutaka Tsutsumi; Yoshiya Yamamoto; Shinichi Ito; Hiroyuki Ohigashi; Souichi Shiratori; Hirohito Naruse; Takanori Teshima
Journal: World J Hepatol Date: 2015-09-28

3. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors: Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal: Blood Date: 2018-10-19 Impact factor: 22.113

Review 4. Hepatitis B virus reactivation with rituximab-containing regimen.

Authors: Yutaka Tsutsumi; Yoshiya Yamamoto; Joji Shimono; Hiroyuki Ohhigashi; Takanori Teshima
Journal: World J Hepatol Date: 2013-11-27

5. Concurrent infection of hepatitis B virus negatively affects the clinical outcome and prognosis of patients with non-Hodgkin's lymphoma after chemotherapy.

Authors: Jie Chen; Jianmin Wang; Jianmin Yang; Weiping Zhang; Xianmin Song; Li Chen
Journal: PLoS One Date: 2013-07-08 Impact factor: 3.240

5 in total